Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Cellectis was founded by André Choulika in 1999. It built up a successful business based on the use of Meganuclease in genome engineering. Cellectis went public in 2007, and raised €21.2 million in a stock offering on Euronext. In 2010, it acquired Cyto Pulse, which had developed a new electroporation technology, and in 2011 it paid €28 million for Cellartis, a Swedish biotechnology company. In January 2011 the company licensed TALEN gene-editing technology from Iowa State University and the University of Minnesota. The company employed nearly 300 people in early 2014. More information...
According to PR-model, cellectis.com is ranked 1,661,638th in multilingual Wikipedia, in particular this website is ranked 1,073,533rd in English Wikipedia.
The website is placed before jm.dk and after 7gardoon.com in the BestRef global ranking of the most important sources of Wikipedia.
